Prepping for a rapid-fire launch, Kite Pharma gets a pass from FDA on axi-cel panel review
The FDA has evidently learned all it wants at this point from its outside oncology experts on CAR-T. Kite Pharma’s closely-watched CAR-T drug axi-cel is getting a pass on an adcomm meeting, which may signal a quick thumbs up from regulators.
Kite $KITE execs think so, saying today that they will be fully launch-ready by September in case an early OK comes through. And that bullish stance earned a 7% boost to its share price today.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.